News Release

Astellas Corrects a Part of Description of Press Release

Tokyo, Japan, December 3, 2014 – Astellas Pharma Inc. (Tokyo: 4503; President and CEO: Yoshihiko Hatanaka) announced that it corrects a part of description of its press release dated December 2, 2014. The detail of correction is provided below.

Details

1. Corrected document

   Press release titled “ENZALUTAMIDE (XTANDI) NOW APPROVED IN EUROPE FOR THE TREATMENT OF MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO ARE CHEMOTHERAPY-NAÏVE”

2. Correction

   The timing of launch had an error and has been corrected as below.

(Error) Astellas expects to launch enzalutamide in the pre-chemotherapy setting in the first European countries, including the UK, from January 2015.

(Correction) Astellas expects to launch enzalutamide in the pre-chemotherapy setting in the first European countries, including the UK, from December 2014.

#######

Contacts for inquiries or additional information
Astellas Pharma Inc. Corporate Communications Tel: +81-3-3244-3201 Fax: +81-3-5201-7473 http://www.astellas.com/en